Valeant Sets Price for SILIQ Injection

- April 21st, 2017

Valeant Pharmaceuticals announced the official price for its SILIQ injection.

Valeant Pharmaceuticals (NYSE:VRX, TSX:VRX) announced it will price its SILIQ injection at $3,500 per month, following the evaluation and approval of its Patient Access and Pricing Committee.
As quoted in the press release:

SILIQ will also be included in the company’s patient access program to further offer financial support and access to patients.  SILIQ, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SILIQ is the only product that included the psoriasis area and severity index (PASI 100) during clinical trials as a primary endpoint. The sales and marketing of SILIQ are expected to commence in the U.S. during the second half of 2017.
“The Patient Access and Pricing Committee was constructed to help our company ensure patients have the best possible access to our products. Our goal with SILIQ is to provide outstanding efficacy while being the most affordable injectable biologic for patients with moderate-to-severe plaque psoriasis,” said Joseph Papa, Chairman and CEO of Valeant.

Click here to read the full press release.


Leave a Reply